Teva unveils new pipeline assets from the NTE program of 2013 in
the 2nd Teva R&D In-Focus Webinar
- December 4th @ 8:00am Eastern Time –
JERUSALEM--(BUSINESS WIRE)--Nov. 19, 2013--
Developing new pipeline assets through the New Therapeutic Entities
(NTE) process, which was launched less than one year ago, is a major
element in Teva's strategy for growth. Join the Teva In-Focus NTE
Webinar on December 4th to learn more about some of the product
candidates that the NTE process has produced in 2013.
In the latest in the Teva In-Focus webinar series, Teva will
outline:
-
The steps in the project concept generation, evaluation and selection
process
-
A few of the projects that have been selected for development
-
The expected contributions of these projects over the next few years
The Teva In-Focus NTE webinar will include an in-depth review of
certain key projects from the NTE program of 2013. It will outline the
global market and unmet needs for each. Highlight the approach and
technologies Teva is using to improve upon known molecules to address
these unmet needs. Finally, it will provide a clear picture of the
development plans and expected benefits for this will create for
clinicians, patients and Teva.
Dr. Michael Hayden, Teva’s President of Global R&D and Chief Scientific
Officer, will lead the webinar and will be joined by key leaders from
Teva’s NTE program.
A question and answer session will follow the presentation.
Webinar access details:
Meeting Title: Teva NTE Webinar
Meeting Date: December
4th, 2013
Meeting Time: 8:00 AM [Eastern Time]
Duration:
1 Hour 30 Minutes
Webcast Link: http://www.media-server.com/m/p/m753rv5e
Dial-in details:
US Toll Free 1-866-318-8620
International
1-617-399-5139
Participant Passcode 92011346
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $20.3 billion
in net revenues in 2012.
Teva's Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are
based on management’s current beliefs and expectations and involve a
number of known and unknown risks and uncertainties that could cause our
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: the ability to
reduce operating expenses to the extent and during the timeframe
intended by our cost restructuring program; our ability to develop and
commercialize additional pharmaceutical products, including our ability
to develop, manufacture, market and sell biopharmaceutical products,
competition for our innovative products, especially COPAXONE® (including
competition from innovative orally-administered alternatives, as well as
from potential purported generic equivalents), competition for our
generic products (including from other pharmaceutical companies and as a
result of increased governmental pricing pressures), competition for our
specialty pharmaceutical businesses, our ability to achieve expected
results through our specialty, including innovative, R&D efforts, the
effectiveness of our patents and other protections for innovative
products, decreasing opportunities to obtain U.S. market exclusivity for
significant new generic products, our ability to identify, consummate
and successfully integrate acquisitions, the effects of increased
leverage as a result of recent acquisitions, the extent to which any
manufacturing or quality control problems damage our reputation for high
quality production and require costly remediation, our potential
exposure to product liability claims to the extent not covered by
insurance, increased government scrutiny in both the U.S. and Europe of
our agreements with brand companies, potential liability for sales of
generic products prior to a final resolution of outstanding patent
litigation, our exposure to currency fluctuations and restrictions as
well as credit risks, the effects of reforms in healthcare regulation
and pharmaceutical pricing and reimbursement, any failures to comply
with complex Medicare and Medicaid reporting and payment obligations,
governmental investigations into sales and marketing practices
(particularly for our specialty pharmaceutical products), uncertainties
surrounding the legislative and regulatory pathways for the registration
and approval of biotechnology based products, adverse effects of
political or economical instability, corruption, major hostilities or
acts of terrorism on our significant worldwide operations, interruptions
in our supply chain or problems with our information technology systems
that adversely affect our complex manufacturing processes, any failure
to retain key personnel or to attract additional executive and
managerial talent, the impact of continuing consolidation of our
distributors and customers, variations in patent laws that may adversely
affect our ability to manufacture our products in the most efficient
manner, potentially significant impairments of intangible assets and
goodwill, potential increases in tax liabilities, the termination or
expiration of governmental programs or tax benefits, environmental risks
and other factors that are discussed in our Annual Report on Form 20-F
for the year ended December 31, 2012 and in our other filings with the
U.S. Securities and Exchange Commission. Forward-looking statements
speak only as of the date on which they are made and the Company
undertakes no obligation to update or revise any forward looking
statement, whether as a result of new information, future events or
otherwise.
Source: Teva Pharmaceutical Industries Ltd.
IR Contacts:
United States
Kevin C. Mannix, 215-591-8912
or
United
States
Ran Meir, 215-591-3033
or
Israel
Tomer
Amitai, 972 (3) 926-7656
or
PR Contacts:
Israel
Iris
Beck Codner, 972 (3) 926-7687
or
United States
Denise
Bradley, 215-591-8974